UNLABELLED: The healthy adult human liver expresses low levels of major histocompatibility complex class II (MHC II) and undetectable levels of immune costimulatory molecules. However, high levels of MHC II, CD40, and B7 family molecules are expressed in the activated Kupffer cells and hepatocytes of patients with viral hepatitis. The precise role of these molecules in viral clearance and immune-mediated liver injury is not well understood. We hypothesized that parenchymal CD40 expression enhances T cell recruitment and effector functions, which may facilitate viral clearance and alleviate liver injury. To test this hypothesis, we generated novel liver-specific, conditional CD40 transgenic mice, and we challenged them intravenously with a recombinant replication-deficient adenovirus carrying Cre recombinase (AdCre). Wild-type mice infected with AdCre developed a relatively mild course of viral hepatitis and recovered spontaneously. CD40 expression in the livers of transgenic animals, however, resulted in CD80 and CD86 expression. The dysregulation of population dynamics and effector functions of intrahepatic lymphocytes (IHLs) resulted in severe lymphocytic infiltration, apoptosis, necroinflammation, and serum alanine aminotransferase elevations in a dose-dependent fashion. To our surprise, an early expansion and subsequent contraction of IHLs (especially CD8(+) and natural killer cells), accompanied by increased granzyme B and interferon-γ production, did not lead to faster viral clearance in CD40 transgenic mice. CONCLUSION: Our results demonstrate that hepatic CD40 expression does not accelerate adenoviral clearance but rather exacerbates liver injury. This study unveils a previously unknown deleterious effect of hepatic CD40 on adenovirus-induced liver inflammation.
UNLABELLED: The healthy adult human liver expresses low levels of major histocompatibility complex class II (MHC II) and undetectable levels of immune costimulatory molecules. However, high levels of MHC II, CD40, and B7 family molecules are expressed in the activated Kupffer cells and hepatocytes of patients with viral hepatitis. The precise role of these molecules in viral clearance and immune-mediated liver injury is not well understood. We hypothesized that parenchymal CD40 expression enhances T cell recruitment and effector functions, which may facilitate viral clearance and alleviate liver injury. To test this hypothesis, we generated novel liver-specific, conditional CD40transgenic mice, and we challenged them intravenously with a recombinant replication-deficient adenovirus carrying Cre recombinase (AdCre). Wild-type mice infected with AdCre developed a relatively mild course of viral hepatitis and recovered spontaneously. CD40 expression in the livers of transgenic animals, however, resulted in CD80 and CD86 expression. The dysregulation of population dynamics and effector functions of intrahepatic lymphocytes (IHLs) resulted in severe lymphocytic infiltration, apoptosis, necroinflammation, and serum alanine aminotransferase elevations in a dose-dependent fashion. To our surprise, an early expansion and subsequent contraction of IHLs (especially CD8(+) and natural killer cells), accompanied by increased granzyme B and interferon-γ production, did not lead to faster viral clearance in CD40transgenic mice. CONCLUSION: Our results demonstrate that hepatic CD40 expression does not accelerate adenoviral clearance but rather exacerbates liver injury. This study unveils a previously unknown deleterious effect of hepatic CD40 on adenovirus-induced liver inflammation.
Authors: Michael R Betts; David A Price; Jason M Brenchley; Karin Loré; F Javier Guenaga; Anna Smed-Sorensen; David R Ambrozak; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup Journal: J Immunol Date: 2004-05-15 Impact factor: 5.422
Authors: Haidong Dong; Gefeng Zhu; Koji Tamada; Dallas B Flies; Jan M A van Deursen; Lieping Chen Journal: Immunity Date: 2004-03 Impact factor: 31.745
Authors: Jalal Ahmed-Choudhury; Clare L Russell; Satinder Randhawa; Lawrence S Young; David H Adams; Simon C Afford; Jalal Ahmed Choudhury Journal: Mol Biol Cell Date: 2003-04 Impact factor: 4.138
Authors: Rachel Kassel; Michael W Cruise; Julia C Iezzoni; Nicholas A Taylor; Timothy L Pruett; Young S Hahn Journal: Hepatology Date: 2009-11 Impact factor: 17.425
Authors: Frauke Borcherding; Martin Nitschke; Gheorghe Hundorfean; Jan Rupp; Dorthe von Smolinski; Katja Bieber; Cees van Kooten; Hendrik Lehnert; Klaus Fellermann; Jürgen Büning Journal: Am J Pathol Date: 2010-02-04 Impact factor: 4.307
Authors: Steven E Raper; Narendra Chirmule; Frank S Lee; Nelson A Wivel; Adam Bagg; Guang-ping Gao; James M Wilson; Mark L Batshaw Journal: Mol Genet Metab Date: 2003 Sep-Oct Impact factor: 4.797
Authors: Robert Thimme; Jens Bukh; Hans Christian Spangenberg; Stefan Wieland; Janell Pemberton; Carola Steiger; Sugantha Govindarajan; Robert H Purcell; Francis V Chisari Journal: Proc Natl Acad Sci U S A Date: 2002-11-19 Impact factor: 11.205
Authors: Meagan J Walsh; Daina M Vanags; Andrew D Clouston; Michelle M Richardson; David M Purdie; Julie R Jonsson; Elizabeth E Powell Journal: Hepatology Date: 2004-05 Impact factor: 17.425